Shared on 02 Nov 25
Fair value Decreased 1.95%Analysts have modestly reduced their price target for Tandem Diabetes Care to $20.64 from $21.05 per share. They cite heightened competitive pressure and tempered profit margin expectations, despite signs of steady revenue growth.
Shared on 18 Oct 25
Fair value Increased 1.38%Pharmacy Channel And Europe Expansion Will Build Future Advantage
The analyst price target for Tandem Diabetes Care has increased modestly, rising by approximately $0.29 to $21.05. Analysts cite healthier revenue and margin expectations, ongoing product launches, and potential policy tailwinds supporting the company's near-term outlook.
Shared on 04 Oct 25
Fair value Decreased 8.21%Pharmacy Channel And Europe Expansion Will Build Future Advantage
Analysts have lowered their price target for Tandem Diabetes Care from approximately $22.62 to $20.76. They cite tempered expectations for growth and profitability due to increased U.S. competition and ongoing commercial transformation.
Shared on 08 Aug 25
Fair value Decreased 19%Pharmacy Channel And Europe Expansion Will Build Future Advantage
Tandem Diabetes Care’s consensus price target has been revised downward as a result of a lower future P/E despite improved net profit margin, with the fair value estimate decreasing from $27.90 to $24.05. What's in the News Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that can result in a discontinuation of insulin delivery, leading to 700 confirmed adverse events and 59 reported injuries (Key Developments, 2025-08-07).
Shared on 01 May 25
Fair value Decreased 30%Pharmacy Channel And Europe Expansion Will Build Future Advantage
Shared on 24 Apr 25
Fair value Decreased 2.80%FDA Approval Of Control-IQ+ Will Expand Market Reach In Type 2 Diabetes
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 3.59%FDA Approval Of Control-IQ+ Will Expand Market Reach In Type 2 Diabetes
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 34%FDA Approval Of Control-IQ+ Will Expand Market Reach In Type 2 Diabetes
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 0.58%FDA Approval Of Control-IQ+ Will Expand Market Reach In Type 2 Diabetes
Shared on 26 Mar 25
Fair value Decreased 11%FDA Approval Of Control-IQ+ Will Expand Market Reach In Type 2 Diabetes
AnalystConsensusTarget made no meaningful changes to valuation assumptions.